SCHEMBL6350601

SCHEMBL6350601

COC(=O)N(CC(=O)c1ccccc1)C(C(N)=O)C(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.42
KDM4E B2RXH2 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
MEN1 O00255 3/20 0.39
MAPT P10636 3/20 0.39
HPGD P15428 2/20 0.39
CYP3A4 P08684 1/20 0.39
ALOX15 P16050 1/20 0.39
CES1 P23141 1/20 0.39
MAPK1 P28482 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
TRPM8 Q7Z2W7 4/20 0.38
NPC1 O15118 5/20 0.38
ALDH1A1 P00352 3/20 0.37
POLB P06746 2/20 0.37
USP2 O75604 1/20 0.37
LMNA P02545 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6350485 0.89 KMT2A (0.44) KMT2AKDM4ESMN1; SMN2MEN1MAPT
SCHEMBL6357950 0.87 ALDH1A1 (0.48) KMT2AKDM4ESMN1; SMN2MEN1MAPT
SCHEMBL6356582 0.86 SLC6A2 (0.43) KMT2ASMN1; SMN2MAPTHPGDTDP1
SCHEMBL6347733 0.85 ALDH1A1 (0.43) KMT2AKDM4ESMN1; SMN2MEN1MAPT
SCHEMBL6347856 0.85 ALDH1A1 (0.43) KMT2AKDM4ESMN1; SMN2MEN1MAPT
SCHEMBL6350864 0.85 TRPM8 (0.47) KMT2AKDM4ESMN1; SMN2MEN1MAPT
SCHEMBL6354208 0.85 ALDH1A1 (0.43) KMT2AKDM4ESMN1; SMN2MEN1MAPT
SCHEMBL6359179 0.85 TRPM8 (0.47) KMT2AKDM4ESMN1; SMN2MEN1MAPT
SCHEMBL6350685 0.84 KMT2A (0.38) KMT2AKDM4ESMN1; SMN2MEN1MAPT
SCHEMBL6359360 0.84 KMT2A (0.38) KMT2AKDM4ESMN1; SMN2MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960575-B2 For use as inhibitors of chymase SANTEN PHARMACEUTICAL CO., LTD. (JP) 2005-11-01 US disclosed
US-20040097496-A1 Novel thiazine derivatives SANTEN PHARMACEUTICAL CO.,LTD. (JP) 2004-05-20 US disclosed
US-6713472-B1 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-03-30 US disclosed
EP-1211249-A1 NOVEL THIAZINE OR PYRAZINE DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097496-A1 Novel thiazine derivatives CMA1, TPSD1, HRH4 KMT2A 3612/4885KDM4E 2934/4885SMN1; SMN2 4138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.